Intercept sells international rights to liver drug in $400M deal

Intercept Pharmaceuticals will sell rights to its liver disease drug Ocaliva outside of the U.S. to U.K.-based Advanz Pharma, which agreed to pay Intercept $405 million upfront in a deal announced by the companies Thursday.